تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
AbbVie Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $453.2B | |
|---|---|---|
| Revenue (ttm) | 64.4B | |
| Net income (ttm) | 6.3B | |
| EPS (ttm) | $3.54 | |
| Shares out | 1.8B | |
| P/E (trailing) | 80.8x | |
| P/E (forward) | 16.1x | |
| Dividend | $6.92 (2.42%) | |
| Volume | 1,928,807 | |
| Beta | 0.23 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B | +2.1% |
| Gross profit | $10.57B | $10.95B | $8.60B | $10.71B | $12.07B | +3.4% |
| Operating income | $17.92B | $18.12B | $12.76B | $9.14B | $15.08B | -4.2% |
| Net income | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B | -22.2% |
| EPS (diluted) | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 | -22.2% |
| EBITDA | $23.93B | $24.17B | $17.17B | $14.91B | $17.63B | -7.4% |
| R&D | $8.05B | $6.51B | $7.68B | $12.79B | $9.10B | +3.1% |
| SG&A | $12.35B | $15.26B | $12.87B | $14.75B | $14.01B | +3.2% |
Recent company headlines from major financial publishers.
The base case remains modal because annual estimates support recovery. It would weaken if growth faded faster after FY2027 or if less revenue became adjusted earnings.
This path needs sustained earnings growth after the explicit estimate period. A rapid mature-growth fade would disconfirm it.
| Ke ↓ / g → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 5.2% | $217 | $235 | $258 | $290 | $336 |
| 6.2% | $183 | $194 | $207 | $224 | $246 |
| 7.2% | $158 | $166 | $180 | $185 | $198 |
| 8.2% | $140 | $146 | $151 | $158 | $167 |
| 9.2% | $126 | $130 | $134 | $139 | $145 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
